United Therapeutics Corporation Stock price

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:53 2024-02-23 pm EST 5-day change 1st Jan Change
227 USD +4.34% Intraday chart for United Therapeutics Corporation +5.73% +3.25%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * 2.68B Sales 2025 * 2.82B Capitalization 10.68B
Net income 2024 * 1.18B Net income 2025 * 1.23B EV / Sales 2024 * 2.69 x
Net cash position 2024 * 3.47B Net cash position 2025 * 3.83B EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
9.65 x
P/E ratio 2025 *
9.27 x
Employees 1,168
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.67%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on United Therapeutics Corporation

1 day+4.34%
1 week+5.73%
Current month+5.71%
1 month+3.52%
3 months-1.77%
6 months-0.86%
Current year+3.25%
More quotes
1 week
213.75
Extreme 213.75
227.75
1 month
208.62
Extreme 208.6249
227.75
Current year
208.62
Extreme 208.6249
231.06
1 year
204.44
Extreme 204.44
261.54
3 years
155.71
Extreme 155.71
283.09
5 years
74.31
Extreme 74.31
283.09
10 years
74.31
Extreme 74.31
283.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 96-06-25
President 52 11-03-31
Director of Finance/CFO 56 12-12-31
Members of the board TitleAgeSince
Director/Board Member 76 01-12-31
Chief Executive Officer 69 96-06-25
Director/Board Member 81 09-12-31
More insiders
Date Price Change Volume
24-02-23 227 +4.33% 524,017
24-02-22 217.6 -0.72% 456,651
24-02-21 219.2 +2.34% 622,521
24-02-20 214.2 -0.27% 581,299

Delayed Quote Nasdaq, February 23, 2024 at 03:59 pm EST

More quotes
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
227 USD
Average target price
286.3 USD
Spread / Average Target
+26.12%
Consensus
  1. Stock
  2. Equities
  3. Stock United Therapeutics Corporation - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW